Cardiogenesis, a leading developer of surgical products and accessories used
in angina-relieving procedures, recently announced that it has received CE MARK
(Conformite Europeenne) approval for the commercial sale of the Pearl Minimally
Invasive TMR delivery systems in European Union member countries. The Pearl
Robotic 5.0 and Thoracoscopic 8.0 delivery systems are designed to reduce the
morbidity and recovery time for patients, while providing the same improved
long term survival and enduring angina benefit achieved with the standard Cardiogenesis
Ho:YAG surgical system.